3-(2,4-dichlorophenyl)-5-methyl-7-(3-pentyl)amino-isoxazolo[4,5-d]pyrimidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2,4-dichlorophenyl)-5-methyl-7-(3-pentyl)amino-isoxazolo[4,5-d]pyrimidine
• 英文别名: N-[3-(2,4-dichlorophenyl)-5-methylisoxazolo[4,5-d]-pyrimidin-7-yl]-N-(1-ethylpropyl)amine；3-(2,4-dichlorophenyl)-5-methyl-N-pentan-3-yl-[1,2]oxazolo[4,5-d]pyrimidin-7-amine
• 化学式: C₁₇H₁₈Cl₂N₄O
• 分子量: 365.262
• InChiKey: LHYHZFIUYDPNKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Isoxazolo [4,5-d] pyrimidines as CRF antagonists
  申请人：——

  公开号：US20020013461A1

  公开（公告）日：2002-01-31

  The present invention describes novel isoxazolo[1,5-a]pyrimidines of formula: 1 wherein R is an aromatic or heteroaromatic ring, or pharmaceutically acceptable salt form thereof, which are useful as CRF antagonists.

  本发明描述了一种新型的异噁唑[1,5-a]嘧啶化合物，化学式为：1，其中R是芳香环或杂环芳基，或其药学上可接受的盐形式，可用作CRF拮抗剂。
• Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
  申请人：Arneric P. Stephen

  公开号：US20050085479A1

  公开（公告）日：2005-04-21

  The present invention provides compositions and methods for the treatment of ischemic mediated central nervous system disorder or injury. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic mediated disorder or injury comprising the administration to a subject of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist or a pharmaceutically acceptable salt or a prodrug thereof.

  本发明提供了治疗缺血介导的中枢神经系统紊乱或损伤的组合物和方法。更具体地说，本发明提供了一种用于治疗中枢神经系统缺血介导的失调或损伤的组合疗法，包括向受试者施用环氧化酶-2 选择性抑制剂和促肾上腺皮质激素释放因子拮抗剂或其药学上可接受的盐或原药。
• US6294671B1
  申请人：——

  公开号：US6294671B1

  公开（公告）日：2001-09-25
• US6589958B1
  申请人：——

  公开号：US6589958B1

  公开（公告）日：2003-07-08
• [EN] COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CORTICOTROPIN RELEASING FACTOR ANTAGONIST FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY<br/>[FR] COMPOSITIONS COMPRENANT UN INHIBITEUR SELECTIF DE LA CYCLOOXYGENASE-2 ET UN ANTAGONISTE DU FACTEUR DE LIBERATION DE LA CORTICOTROPINE POUR LE TRAITEMENT DE TROUBLES OU DE LESIONS DU SYSTEME NERVEUX CENTRAL D'ORIGINE ISCHEMIQUE
  申请人：PHARMACIA CORP

  公开号：WO2005020910A2

  公开（公告）日：2005-03-10

  The present invention provides compositions and methods for the treatment of ischemic mediated central nervous system disorder or injury. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic mediated disorder or injury comprising the administration to a subject of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist or a pharmaceutically acceptable salt or a prodrug thereof.